Lead Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

No

•Participants who meet the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-V) diagnostic criteria for schizophrenia confirmed by the Mini International Neuropsychiatric Interview (M.I.N.I) Version 7.0.2
•Participants must have well-controlled positive symptoms and prominent negative symptoms as defined by Positive and Negative Syndrome Scale (PANSS) criteria.
•Participants must have a reliable informant (e.g., case manager, social worker, family member). The informant should be able to spend an adequate amount of time with the participant to be able to address behaviors, activities, and symptoms.

•Participants with current major depressive disorder (MDD)
•Participants with pseudo-parkinsonism secondary to their ongoing antipsychotic medication
•Participants currently using anticholinergic medications
•Participants recently hospitalized as in-patients

Related studies

NCT07565428 · Negative Symptoms of Schizophrenia

NCT07645443 · Early Onset Psychosis, First Psychotic Episode Within the Last 5 Years, and more

NCT07288333 · Schizophrenia

NCT07105098 · Schizophrenia

NCT06743711 · Severe Mental Illness, Schizophrenia Spectrum &Amp; Other Psychotic Disorders, and more

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia